Physician profile
Daniel Bergman
NPI 1053843169
$1,617.06
in general payments reported to CMS, 2019-2025
19 companies · $936 in 2025
The $936 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2022: $233 · 2024: $101 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,036.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $289.99 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Allergan, INC. | $222.34 | 2019 | |
| Bioventus LLC | $148.87 | 2022 | |
| Genzyme Corporation | $124.57 | 2019 | |
| Novartis Pharmaceuticals Corporation | $106.79 | 2025 | |
| Galderma Laboratories, L.P. | $99.33 | 2025 | Nemluvio |
| Abbvie INC. | $97.87 | 2025 | |
| Gilead Sciences, INC. | $84.42 | 2022 | |
| Arcutis Biotherapeutics, INC. | $79.45 | 2025 | Zoryve |
| Merz North America, INC. | $75.50 | 2025 | |
| Incyte Corporation | $70.24 | 2025 | Opzelura |
| Amgen INC. | $66.69 | 2025 | Otezla |
| Organogenesis INC. | $30.51 | 2025 | Affinity |
| Regeneron Healthcare Solutions, INC. | $28.06 | 2024 | Libtayo |
| Journey Medical Corporation | $23.86 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $23.63 | 2025 | Tremfya |
| Lilly USA, LLC | $20.43 | 2025 | Ebglyss |
| Pfizer INC. | $15.23 | 2025 | |
| Mayne Pharma Commercial LLC | $9.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bergman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.